Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Heart Diseases 3Vascular Diseases 2Small Cell Lung Carcinoma 2Leukemia, Myeloid, Acute 2Cardiovascular Diseases 2Cardiotoxicity 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Cancer Resectable 1Ovarian Carcinosarcoma 1Noonan Syndrome 5 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metabolic Diseases 1Liver Neoplasms 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Immune-related Adverse Event 1Hematologic Neoplasms 1Heart Failure 1Esophageal Neoplasms 1Early Hormone Receptor-positive Breast Cancer 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1

Interventions

Cytarabine 84Etoposide 31Daunorubicin 31Mitoxantrone 26Idarubicin 26Filgrastim 24Busulfan 20Peripheral Blood Stem Cell Transplantation 19Cyclophosphamide 17fludarabine phosphate 15Gemtuzumab 14tipifarnib 11Azacitidine 11Methotrexate 10Clofarabine 10sargramostim 9Gene Expression Profiling 9Flow Cytometry 9Cyclosporine 9Tacrolimus 8Radiotherapy 8Granulocyte Colony-Stimulating Factor 7Decitabine 7Antilymphocyte Serum 7alvocidib 6Topotecan 6Bortezomib 6Arsenic Trioxide 6valspodar 5aldesleukin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Monocytic, Acute × Antineoplastic Agents × Clear all
NCT00831766 2020-12-22

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
51 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡